Literature DB >> 21495249

Dihydrofolate reductase transcript level is not suitable for methotrexate-resistance prediction in choriocarcinoma cell line.

Bing Han1, Yang Xiang, Yun Wang, Zheng Wang, Hao Zhang, Shangzhi Huang.   

Abstract

INTRODUCTION: To assess whether dihydrofolate reductase (DHFR) expression is correlated with the concentration of methotrexate (MTX) exposure and the resistance index during the establishment of MTX-resistant human choriocarcinoma JeG-3 cell line.
METHODS: Two series of different MTX-resistant JeG-3 sublines were established by intermittent- and consecutive-inducing methods. Quantitative real-time reverse transcription polymerase chain reaction was used to measure DHFR messenger RNA expression in the sublines during different concentrations of MTX exposure. [beta]-Human chorionic gonadotropin ([beta]-HCG) secretion in these cell lines were detected by using chemoluminescence method.
RESULTS: In the 2 series of MTX-resistant cell lines, the same dynamic profiling of [beta]-HCG secretion and DHFR transcript level were found: At a certain range of concentration, the upward [beta]-HCG secretion and the messenger RNA level of DHFR were correlated with the dose of MTX exposing. However, once the concentration of MTX exceeded this range, the expression would not increase but decrease sharply. According to the concentration of MTX exposure from low to high, the multiples of [beta]-HCG increases were 1.86-, 5.15-, 8.38-, 64.17-, 2.6-, and 0.78-fold for intermittent induction and 22.05-, 6.12-, 5.80-, and 1.77-fold for continuous induction; the multiples of DHFR gene expression increases were 12.84-, 99.02-, 129.01-, 177.63-, 420.78-, and 86.09-fold for intermittent induction and 9.59-, 20.56-, 96.05-, and 58.72-fold for continuous induction.
CONCLUSIONS: The transcript level of DHFR gene only correlated with MTX drug resistance at a certain phase. It would be of limited use as a biomarker for the MTX-based chemoresistance prediction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21495249     DOI: 10.1111/igc.0b013e3181f05128

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  5 in total

1.  Methotrexate induces DNA damage and inhibits homologous recombination repair in choriocarcinoma cells.

Authors:  Lisha Xie; Tiancen Zhao; Jing Cai; You Su; Zehua Wang; Weihong Dong
Journal:  Onco Targets Ther       Date:  2016-11-17       Impact factor: 4.147

2.  SLAMF1 Promotes Methotrexate Resistance via Activating Autophagy in Choriocarcinoma Cells.

Authors:  Dazun Shi; Yu Zhang; Yan Tian
Journal:  Cancer Manag Res       Date:  2020-12-30       Impact factor: 3.989

3.  ATR and CDK4/6 inhibition target the growth of methotrexate-resistant choriocarcinoma.

Authors:  Marina Georgiou; Panagiota Ntavelou; William Stokes; Rajat Roy; Geoffrey J Maher; Tsvetana Stoilova; Josephine A M Y Choo; Callum P Rakhit; Miguel Martins; Paul Ajuh; Neil Horowitz; Ross S Berkowitz; Kevin Elias; Michael J Seckl; Olivier E Pardo
Journal:  Oncogene       Date:  2022-03-18       Impact factor: 8.756

4.  AKR1C3 overexpression mediates methotrexate resistance in choriocarcinoma cells.

Authors:  Jing Zhao; Yang Xiang; Changji Xiao; Peng Guo; Dan Wang; Ying Liu; Yun Shen
Journal:  Int J Med Sci       Date:  2014-08-13       Impact factor: 3.738

5.  CD105 overexpression mediates drug-resistance in choriocarcinoma cells through BMP9/Smad pathway.

Authors:  Xiaoyu Wang; Liju Zong; Wenze Wang; Junjun Yang; Yang Xiang
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.207

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.